NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag
- First Posted Date
- 2004-11-24
- Last Posted Date
- 2025-06-19
- Target Recruit Count
- 57
- Registration Number
- NCT00097474
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
Completed
- Conditions
- ThromboembolismUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-11-12
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00096590
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerStage IV Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00096499
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00096447
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Sorafenib in Treating Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Male Breast CancerStage IV Breast CancerRecurrent Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00096434
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00096551
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the Larynx
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00096512
- Locations
- 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7Metastatic Malignant Neoplasm in the Brain
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00096265
- Locations
- 🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇺🇸Parkview Hospital Randallia, Fort Wayne, Indiana, United States
🇺🇸Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Myeloblastic Leukemia With Maturation (M2)de Novo Myelodysplastic SyndromesUntreated Adult Acute Myeloid LeukemiaAdult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Pure Erythroid Leukemia (M6b)Childhood Myelodysplastic SyndromesAdult Acute Eosinophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT00096122
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2
Completed
- Conditions
- Stage IV Endometrial CarcinomaEndometrial AdenocarcinomaRecurrent Endometrial Carcinoma
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00095979
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States